T7RNA polymerase mutant, mRNA, gene, expression vector and cell

A gene expression and polymerase technology, applied in genetic engineering, plant gene improvement, recombinant DNA technology, etc., can solve the problem of transcriptional activity decline

Active Publication Date: 2021-06-08
左炽健
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although wild-type T7 RNA polymerase can also use the above-mentioned modified nucleotide substrates to synthesize m

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T7RNA polymerase mutant, mRNA, gene, expression vector and cell
  • T7RNA polymerase mutant, mRNA, gene, expression vector and cell
  • T7RNA polymerase mutant, mRNA, gene, expression vector and cell

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0056] Example 1: Construction of T7 RNA polymerase mutant screening system

[0057] Dmitry Temiakov et al. used the co-crystallized structure of T7 RNA polymerase and substrate analogs, combined with site-directed mutagenesis technology, to clarify the key mechanism and important amino acid sites of T7 RNA polymerase for substrate selectivity, including Y639, M635, R632, K631, Y571, R627, K472, etc. (Dmitry Temiakov et al., Cell, (2004) 116, 381-391). According to published literature reports such as Ikeda (Ikeda, R.A.et al.Biochemistry, 31:9073-9080,1992 and Ikeda, R.A.etal., Nucl.Acid.Res., 20:2517-2524,1992, JijumonChelliserrykattil etc., Nat Biotechnol.2004 22(9):1155-60.), through the dual-plasmid screening system based on T7 RNA polymerase on the transcriptional activity of T7 promoter, the functional screening of T7 RNA polymerase mutants can be realized. The present invention adopts the same principle and constructs a dual-plasmid screening system for screening T7 RN...

example 2

[0068] Example 2: Protein expression, purification and preliminary functional identification of T7 RNA polymerase mutants

[0069] Since the mutant library of the T7-encoding gene is constructed for amino acids that are key to substrate selectivity, the T7 RNA polymerase mutant obtained through the preliminary screening of Example 1 above is considered to have the ability to utilize modified nucleotides to transcribe Potential for synthetically modified mRNA. By expanding the culture of the T7 RNA polymerase mutant strains screened above, and using the 6xHis tag attached to the C-terminus of the pET21a(+) vector, based on the affinity between the His tag and the Ni-NTA Agarose purification medium, the T7 RNA Polymerase mutant proteins were purified. The specific steps are as follows: collect the bacteria by centrifugation (9000rpm, 10 minutes of centrifugation), resuspend the bacteria in lysis buffer (50mM Tris, pH=8.0, 50mM NaCl), sonicate the bacteria, and centrifuge (12000...

example 3

[0070] Example 3: T7 RNA polymerase mutants use modified nucleotides to transcribe and synthesize luciferase modified mRNA, and compare the transcriptional activity with wild-type T7 RNA polymerase

[0071]The T7 promoter on pET28a was used to test the transcriptional activity of the T7 RNA polymerase mutant by linking the luciferase gene shown in SEQ ID No.6. According to reports by Gallie G.R et al. (Gallie G.R et al., Gene, 1999,165,233-238), the 5' untranslated sequence (5' UTR of tobacco mosaic virus (TEV), its DNA sequence is shown in SEQ ID No.6) Can be used to mediate post-transcriptional translation. Therefore, the 5'UTR of TEV is used here to mediate the translation of luciferase. TEV 5'UTR is shown in SEQ ID No:7 to SEQ ID No:8. In addition, a 100nt poly(dT) was introduced into the transcription template, and a 100nt poly(A) tail structure was obtained through complementary pairing during the transcription process. The 5'UTR, luciferase gene and 100 nt poly(dT) D...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A T7 RNA polymerase mutant disclosed by the invention is a mutant obtained by mutating a mutant amino acid in a wild T7 RNA polymerase amino acid sequence as shown in SEQ ID No: 1, and the mutant amino acid is one or a combination of more of Y639T, M635V, R632Q, K631L, Y571T, R627E and K472S. The T7 RNA polymerase mutant has RNA polymerase activity based on a T7 promoter, and one or more modified nucleotides can be used as substrates to synthesize modified messenger ribonucleic acid. Compared with a wild type T7 RNA polymerase, the T7 RNA polymerase mutant has the advantage that the mRNA synthesis efficiency based on the modified nucleotide substrate is obviously enhanced.

Description

[0001] Prior application: 201911237625.9 technical field [0002] The invention relates to the fields of enzyme engineering and messenger ribonucleic acid (mRNA) in vitro transcription, in particular to enzyme mutants, mRNAs, genes, expression vectors and T7 RNA polymerase mutants related to the T7 RNA polymerase mutants that use modified nucleotides as substrates to transcribe and synthesize mRNAs. cell. Background technique [0003] As early as the 1970s, RNA synthesized in vitro was demonstrated to be delivered into cells by transfection techniques (Dubes GR, Wegrzyn RJ (1978) Protoplasma 96:209-223). However, it was not until 1992 that in vitro transcribed RNA was demonstrated to exert specific physiological effects through delivery into cells (Jirikowski GF (1992) Science 255:996–998). However, the application of in vitro transcribed mRNA as an antigen-encoding or recombinant protein drug in drug therapy and vaccines has not attracted more and more attention until afte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N9/12C12N15/54C12N15/70C12N15/85C12N1/21C12N5/10C12R1/19
CPCC12N9/1247C12Y207/07006
Inventor 左炽健刘楠
Owner 左炽健
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products